GB0031315D0 - Indole derivatives - Google Patents

Indole derivatives

Info

Publication number
GB0031315D0
GB0031315D0 GBGB0031315.5A GB0031315A GB0031315D0 GB 0031315 D0 GB0031315 D0 GB 0031315D0 GB 0031315 A GB0031315 A GB 0031315A GB 0031315 D0 GB0031315 D0 GB 0031315D0
Authority
GB
United Kingdom
Prior art keywords
indole derivatives
neurodegenerative
solvates
immunological
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0031315.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0031315.5A priority Critical patent/GB0031315D0/en
Publication of GB0031315D0 publication Critical patent/GB0031315D0/en
Priority to JP2002551528A priority patent/JP4460830B2/ja
Priority to AU2002217286A priority patent/AU2002217286A1/en
Priority to US10/450,894 priority patent/US7288564B2/en
Priority to ES01271354T priority patent/ES2282195T3/es
Priority to AT01271354T priority patent/ATE353875T1/de
Priority to PCT/GB2001/005701 priority patent/WO2002050031A1/en
Priority to DE60126652T priority patent/DE60126652T2/de
Priority to EP01271354A priority patent/EP1343757B1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
GBGB0031315.5A 2000-12-21 2000-12-21 Indole derivatives Ceased GB0031315D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB0031315.5A GB0031315D0 (en) 2000-12-21 2000-12-21 Indole derivatives
JP2002551528A JP4460830B2 (ja) 2000-12-21 2001-12-20 インドール誘導体
AU2002217286A AU2002217286A1 (en) 2000-12-21 2001-12-20 Indole derivatives
US10/450,894 US7288564B2 (en) 2000-12-21 2001-12-20 Indole derivatives
ES01271354T ES2282195T3 (es) 2000-12-21 2001-12-20 Derivados de indol.
AT01271354T ATE353875T1 (de) 2000-12-21 2001-12-20 Indolderivate
PCT/GB2001/005701 WO2002050031A1 (en) 2000-12-21 2001-12-20 Indole derivatives
DE60126652T DE60126652T2 (de) 2000-12-21 2001-12-20 Indolderivate
EP01271354A EP1343757B1 (en) 2000-12-21 2001-12-20 Indole derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0031315.5A GB0031315D0 (en) 2000-12-21 2000-12-21 Indole derivatives

Publications (1)

Publication Number Publication Date
GB0031315D0 true GB0031315D0 (en) 2001-02-07

Family

ID=9905643

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0031315.5A Ceased GB0031315D0 (en) 2000-12-21 2000-12-21 Indole derivatives

Country Status (9)

Country Link
US (1) US7288564B2 (https=)
EP (1) EP1343757B1 (https=)
JP (1) JP4460830B2 (https=)
AT (1) ATE353875T1 (https=)
AU (1) AU2002217286A1 (https=)
DE (1) DE60126652T2 (https=)
ES (1) ES2282195T3 (https=)
GB (1) GB0031315D0 (https=)
WO (1) WO2002050031A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
SE0402284D0 (sv) * 2004-09-21 2004-09-21 Astrazeneca Ab New heterocyclic amides
CA2586156A1 (en) * 2004-11-04 2006-05-18 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
US8053454B2 (en) 2005-10-06 2011-11-08 Exelixis, Inc. Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3
TW200736227A (en) * 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
EP2013169B1 (en) * 2006-04-24 2012-08-22 Merck Canada Inc. Indole amide derivatives as ep4 receptor antagonists
TWI433839B (zh) * 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
US20100074896A1 (en) * 2006-11-30 2010-03-25 The Johns Hopkins University Antagonists of pge2 ep3 receptors
US20080167377A1 (en) 2006-12-15 2008-07-10 Alessandra Gaiba Novel compounds
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
JP5408434B2 (ja) * 2007-07-03 2014-02-05 アステラス製薬株式会社 アミド化合物
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
EP2565191B1 (en) 2008-05-14 2014-10-08 Astellas Pharma Inc. 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
JPWO2010087425A1 (ja) 2009-01-30 2012-08-02 国立大学法人京都大学 前立腺癌の進行抑制剤および進行抑制方法
WO2011047156A1 (en) * 2009-10-15 2011-04-21 Hercules Technology Management Co V, Inc. Sepiapterin reductase inhibitors for the treatment of pain
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
SG11201506687RA (en) 2013-03-15 2015-09-29 Plexxikon Inc Heterocyclic compounds and uses thereof
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
WO2018216640A1 (ja) * 2017-05-22 2018-11-29 小野薬品工業株式会社 Ｅｐ４アンタゴニスト
JP7675519B2 (ja) 2017-10-13 2025-05-13 オプナ バイオ ソシエテ アノニム キナーゼを調節するための化合物の固体形態
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4251446A (en) * 1977-03-01 1981-02-17 Sterling Drug Inc. Phthalide compounds, processes and marking systems
US4322352A (en) * 1979-04-04 1982-03-30 Sterling Drug Inc. Indolyl phthalide compounds
JPS62138469A (ja) * 1985-12-11 1987-06-22 Yoshitomi Pharmaceut Ind Ltd インド−ル誘導体
US5075313A (en) * 1990-09-13 1991-12-24 Eli Lilly And Company 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
GB9022785D0 (en) * 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
CA2240115A1 (en) * 1995-12-14 1997-06-19 Wallace T. Ashton Antagonists of gonadotropin releasing hormone
EP0922028A1 (en) * 1996-08-26 1999-06-16 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
JPH1171336A (ja) * 1997-06-25 1999-03-16 Mitsubishi Chem Corp アミド誘導体
WO2000006550A1 (en) * 1998-07-31 2000-02-10 Nippon Soda Co., Ltd. Phenylazole compounds, process for producing the same and drugs for hyperlipemia
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
AU1444200A (en) * 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for inhibiting bone resorption
GB9902455D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
CA2420042A1 (en) * 2000-08-22 2003-02-18 Mikio Ogawa Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient
US7157487B2 (en) * 2000-12-28 2007-01-02 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors

Also Published As

Publication number Publication date
JP4460830B2 (ja) 2010-05-12
AU2002217286A1 (en) 2002-07-01
ES2282195T3 (es) 2007-10-16
US20040092569A1 (en) 2004-05-13
EP1343757A1 (en) 2003-09-17
US7288564B2 (en) 2007-10-30
ATE353875T1 (de) 2007-03-15
WO2002050031A1 (en) 2002-06-27
JP2004517098A (ja) 2004-06-10
DE60126652D1 (de) 2007-03-29
DE60126652T2 (de) 2008-02-28
EP1343757B1 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
GB0031315D0 (en) Indole derivatives
GB0031302D0 (en) Napthalene derivatives
JO2372B1 (en) Source drugs of 4-phenylpyridine derivatives
MXPA03007621A (es) Antagonistas nr2b de n-metil-d-aspartato no arilheterociclicos n-sustituidos.
MY133996A (en) Compounds for the treatment of ischemia
BG104278A (en) Methods and intermediate compounds for the preparation of anti-cancer compounds
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
PL366430A1 (en) Sustained release formulations of oxymorphone
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
MXPA04003439A (es) Compuestos de maleimida 3,4 disustituidos como antagonistas de receptor de quimiocina cxc.
AU2001271706A1 (en) Use of substituted indole compounds for treating breast disorders
TR200001906T2 (tr) Koks-Inhibitörleri olarak 2,3-ikameli indol bileşikleri.
MXPA02009552A (es) Derivados de imidazopiridina alquilada.
MXPA02009551A (es) Profarmacos de derivados de imidazopiridina.
PL335699A1 (en) Tetrahydropyridic compounds
DE50008020D1 (de) Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten
MXPA03003971A (es) Derivados de indol como inhibidores de pde5.
IL154755A0 (en) Antitumor theraphy comprising distamycin derivatives
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
SG148840A1 (en) Indole derivatives useful for the treatment of cns disorders
AP2001002369A0 (en) Pharmaceutical complex.
BG106078A (en) Thio-oxindole derivatives
AU3476599A (en) Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
YU26001A (sh) Derivati ureidopiperidina kao selektivni antagonisti ljudskih nk3 receptora

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)